表紙
市場調查報告書
商品編碼
1028112

HER2 陽性乳腺癌市場:到 2030 年的流行病學預測

HER2-Positive Breast Cancer - Epidemiology Forecast to 2030

出版日期: | 出版商: GlobalData | 英文 61 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

乳腺癌是全球第二大常見癌症,是全球女性最常見的癌症,佔女性所有癌症的 25.2%,影響了很多人,我生病了。乳腺癌根據人類表皮生長因子受體 2 (HER2) 和激素受體 (HR) 的狀態進行分類(美國癌症協會,2019 年)。

2020年,8個主要市場(8MM:美國、法國、德國、意大利、西班牙、英國、日本和中國城市地區)的HER2/HR陽性乳腺癌診斷數為97,308例。這將是 2030 年的 113,608 例,預計年增長率(AGR)為 1.68%。此外,HER2陽性/HR陰性乳腺癌確診病例數將從2020年的53824例增加到2030年的63106例,AGR為1.72%。這一增長是由於八個國家的乳腺癌患病率逐漸上升以及每個市場的人口變化。早期診斷和開發更有效的治療方法有望提高 HER2 陽性乳腺癌的生存率。

本報告探討了 HER2 陽性乳腺癌市場,並提供了八個主要市場的 HER2 陽性風險因素、全球趨勢、流行病學預測等。

目錄

目錄

  • 關於全球數據

    第 1 章 HER2 陽性乳腺癌:執行摘要

  • 概述
  • 相關報導
  • 未來報告

    第 2 章流行病學

  • 疾病背景
  • 風險因素和合併症
  • 世界趨勢和歷史趨勢
  • 預測性調查方法
    • 使用的來源
    • 預測的先決條件和方法
  • 所有侵襲性和 HER2 陽性乳腺癌的流行病學預測(2020-2030)
    • 診斷所有浸潤性乳腺癌
    • 所有浸潤性乳腺癌的特定年齡診斷病例
    • HER2陽性/HR陽性乳腺癌的診斷
    • HER2陽性/HR陰性乳腺癌的診斷
    • HER2 陽性/HR 陽性乳腺癌確診病例,按分期
    • HER2陽性/HR陰性乳腺癌的診斷
    • HER2 陽性/HR 陽性乳腺癌確診病例(按更年期狀態)
    • 按更年期狀態診斷的 HER2 陽性/HR 陰性乳腺癌病例
    • 通過 PD-1 和 PD-L1 表達診斷 HER2 陽性乳腺癌
    • Ki67 表達的 HER2 陽性乳腺癌的診斷
    • 具有 NTRK 和 RET 表達的 HER2 陽性乳腺癌的診斷
    • HER2陽性乳腺癌骨轉移的診斷
    • HER2陽性乳腺癌腦/中樞神經系統轉移的診斷
    • IHC3 陽性表達的 HER2 陽性乳腺癌的診斷
    • 5 年內診斷為 HER2 陽性乳腺癌的常見病例
  • 討論
    • 流行病學預測見解
    • COVID-19 的影響
    • 分析的局限性
    • 分析的優勢

第 3 章附錄

  • 參考文獻
  • 關於作者
    • 流行病學家
    • 審稿人
    • 治療分析和流行病學世界總監
    • 全球醫療保健業務和戰略主管兼執行副總裁
  • 聯繫我們
目錄
Product Code: GDHCER281-21

Breast cancer is the second most common cancer in the world and the most common cancer in women worldwide, accounting for 25.2% of all incident cases of female cancers, making the disease exceedingly prevalent. Breast cancer is classified based on human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status (American Cancer Society, 2019). HER2-/HR+ and HER2-/HR- were analyzed in the HER2-negative breast cancer report. This report explores HER2-positive breast cancer, namely, HER2+/HR+ and HER2+/HR- breast cancer.

GlobalData epidemiologists used age- and sex-specific diagnosed incidence and prevalence rates to forecast the diagnosed incident and prevalent cases, taking into account the significant relationship between age and HER2-positive breast cancer. GlobalData epidemiologists applied country-specific incidence rates of HER2-positive breast cancer wherever available, to each country's population to obtain the number of estimated diagnosed incident cases.

The following data describes epidemiology of HER2+/HR+ and HER2+/HR- cases. In 2020, the 8MM had 97,308 diagnosed incident cases of HER2/HR+ breast cancer. This is expected to increase to 113,608 diagnosed incident cases by 2030, at an Annual Growth Rate (AGR) of 1.68%. In the 8MM, the diagnosed incident cases of HER2+/HR- breast cancer will increase from 53,824 cases in 2020 to 63,106 cases in 2030, at an AGR of 1.72%. This increase is partly attributed to the moderately rising trend in historical incidence in the 8MM, combined with underlying demographic changes in the respective markets. The early diagnosis and development of more effective therapies would improve survival from HER2-positive breast cancer.

Scope

  • HER2-Positive Breast Cancer Epidemiology Report provides an overview of the risk factors and global trends of HER2-positive in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Urban China).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 8MM: diagnosed incident cases of all invasive, HER2+/HR+, and HER2+/HR- breast cancer; diagnosed five-year prevalent cases of HER2+/HR+, and HER2+/HR- breast cancer; and diagnosed incident cases of HER2+/HR+ and HER2+/HR- breast cancer by cancer staging. Additionally, diagnosed incident cases of HER2+HR+ and HER2+/HR- breast cancer cases are further segmented by metastasis, and biomarker expression. HER2+/HR+ and HER2+/HR- breast cancer cases are also segmented by menopausal status.
  • The HER2-Positive Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The HER2-Positive Breast Cancer Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global HER2-positive breast cancer market.
  • Quantify patient populations in the global HER2-positive market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the HER2-positive cancer stages that present the best opportunities for HER2- positive therapeutics in each of the markets covered.
  • Understand magnitude of HER2-positive breast cancer market by biomarkers.

Table of Contents

Table of Contents

  • | About GlobalData
  • 1 HER2-Positive Breast Cancer: Executive Summary
  • 1.1 Catalyst
  • 1.2 Related Reports
  • 1.3 Upcoming Reports
  • 2 Epidemiology
  • 2.1 Disease Background
  • 2.2 Risk Factors and Comorbidities
  • 2.3 Global and Historical Trends
  • 2.4 Forecast Methodology
    • 2.4.1 Sources Used
    • 2.4.2 Forecast Assumptions and Methods
  • 2.5 Epidemiological Forecast for All Invasive and HER2-Positive Breast Cancer (2020-2030)
    • 2.5.1 Diagnosed Incident Cases of All Invasive Breast Cancer
    • 2.5.2 Age-Specific Diagnosed Incident Cases of All Invasive Breast Cancer
    • 2.5.3 Diagnosed Incident Cases of HER2+/HR+ Breast Cancer
    • 2.5.4 Diagnosed Incident Cases of HER2+/HR- Breast Cancer
    • 2.5.5 Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Stages
    • 2.5.6 Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Stages
    • 2.5.7 Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Menopausal Status
    • 2.5.8 Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Menopausal Status
    • 2.5.9 Diagnosed Incident Cases of HER2-Positive Breast Cancer by PD-1 and PD-L1 Expression
    • 2.5.10 Diagnosed Incident Cases of HER2-Positive Breast Cancer with Ki67 Expression
    • 2.5.11 Diagnosed Incident Cases of HER2-Positive Breast Cancer with NTRK and RET Expression
    • 2.5.12 Diagnosed Incident Cases of HER2-Positive Breast Cancer with Bone Metastasis
    • 2.5.13 Diagnosed Incident Cases of HER2-Positive Breast Cancer with Brain/CNS Metastasis
    • 2.5.14 Diagnosed Incident Cases of HER2-Positive Breast Cancer with IHC3+ Expression
    • 2.5.15 Five-Year Diagnosed Prevalent Cases of HER2-Positive Breast Cancer
  • 2.6 Discussion
    • 2.6.1 Epidemiological Forecast Insight
    • 2.6.2 COVID-19 Impact
    • 2.6.3 Limitations of Analysis
    • 2.6.4 Strengths of Analysis

3 Appendix

  • 3.1 Bibliography
  • 3.2 About the Authors
    • 3.2.1 Epidemiologist
    • 3.2.2 Reviewers
    • 3.2.3 Global Director of Therapy Analysis and Epidemiology
    • 3.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 3.3 Contact Us

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for All Invasive HER2-Positive Breast Cancer

List of Figures

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of HER2+/HR+ Breast Cancer, Women, N, Ages ≥18 Years, 2020 and 2030
  • Figure 2: 8MM, Diagnosed Incident Cases of HER2+/HR- Breast Cancer, Women, N, Ages ≥18 Years, 2020 and 2030
  • Figure 3 : 8MM, Diagnosed Incidence of HER2+/HR+ Breast Cancer, Ages ≥18 Years, Women, Cases per 100,000 Population, 2010-2030
  • Figure 4: 8MM, Diagnosed Incidence of HER2+/HR- Breast Cancer, Ages ≥18 Years, Women, Cases per 100,000 Population, 2010-2030
  • Figure 5: 8MM, Sources Used and Not Used for Diagnosed Incident Cases of All Invasive Breast Cancer
  • Figure 6: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer
  • Figure 7: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by Stage
  • Figure 8: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by Menopausal Status
  • Figure 9: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by PD-1 and PD-L1 Expression
  • Figure 10: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by Ki67, NTRK, and RET Expression
  • Figure 11: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by Bone and Brain Metastasis
  • Figure 12: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by IHC3+ Expression
  • Figure 13: 8MM, Sources Used for Five-Year Diagnosed Prevalent Cases of HER2+/HR+ and HER2+/HR- Breast Cancer
  • Figure 14: 8MM, Diagnosed Incident Cases of All Invasive Breast Cancer, Women, Ages ≥18 Years, N, 2020
  • Figure 15: 8MM, Age-Specific Diagnosed Incident Cases of All Invasive Breast Cancer, Women, Ages ≥18 Years, N, 2020
  • Figure 16: 8MM, Diagnosed Incident Cases of HER2+/HR+ Breast Cancer, Women, Ages ≥18 Years, N, 2020
  • Figure 17: 8MM, Diagnosed Incident Cases of HER2+/HR- Breast Cancer, Women, Ages ≥18 Years, N, 2020
  • Figure 18: 8MM, Proportion of Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Stage, Women, Ages ≥18 Years, N, 2020
  • Figure 19: 8MM, Proportion of Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Stage, Women, Ages ≥18 Years, N, 2020
  • Figure 20: 8MM, Proportion of Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Menopausal Status, Women, Ages ≥18 Years, %, 2020
  • Figure 21: 8MM, Proportion of Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Menopausal Status, Women, Ages ≥18 Years, %, 2020
  • Figure 22: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer by PD-1 and PD-L1 Expression, Women, Ages ≥18 Years, N, 2020
  • Figure 23: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with Ki67 Expression, Women, Ages ≥18 Years, N, 2020
  • Figure 24: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with NTRK and RET Expression, Women, Ages ≥18 Years, N, 2020
  • Figure 25: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with Bone Metastasis, Women, Ages ≥18 Years, N, 2020
  • Figure 26: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with Brain/CNS Metastasis, Women, Ages ≥18 Years, N, 2020
  • Figure 27: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with IHC3+ Expression, Women, Ages ≥18 Years, N, 2020
  • Figure 28: 8MM, Five-Year Diagnosed Prevalent Cases of HER2-Positive Breast Cancer, Women, Ages ≥18 Years, N, 2020